{"id":"NCT02574455","sponsor":"Gilead Sciences","briefTitle":"Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)","officialTitle":"An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-07","primaryCompletion":"2020-03-30","completion":"2020-12-08","firstPosted":"2015-10-12","resultsPosted":"2021-04-30","lastUpdate":"2022-06-15"},"enrollment":529,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Sacituzumab govitecan","otherNames":["IMMU-132","TrodelvyÂ®"]},{"type":"DRUG","name":"Eribulin","otherNames":["Halaven"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]},{"type":"DRUG","name":"Vinorelbine","otherNames":["Navelbine"]}],"arms":[{"label":"Sacituzumab Govitecan","type":"EXPERIMENTAL"},{"label":"Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free survival (PFS) in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) previously treated with at least two systemic chemotherapy regimens for unresectable, locally advanced or metastatic disease, and without brain metastasis at baseline.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population","timeFrame":"From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)","effectByArm":[{"arm":"Sacituzumab Govitecan","deltaMin":5.6,"sd":null},{"arm":"Treatment of Physician's Choice (TPC)","deltaMin":1.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":7},"locations":{"siteCount":230,"countries":["United States","Belgium","Canada","France","Germany","Spain","United Kingdom"]},"refs":{"pmids":["30786188","39324726","38664404","38422473","35545724","34467774","33882206","33093337","33070624"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":69,"n":258},"commonTop":["Nausea","Fatigue","Diarrhoea","Neutropenia","Anaemia"]}}